Horizon 2020
The EU Framework Programme for Research and Innovation

Navigation path

New device VIGI'FALL will make growing older safer thanks to EU funding

Article

The FallWatch Consortium brings together a wealth of European technology and expertise in a tiny triangular patch called Vigi’Fall that can be worn by the user in a non-intrusive, permanent manner.

Unique Vigi’Fall fall detection solution could help save 500,000 hospitalisations and 40,0001 premature deaths caused by falls in Europe every year.

The FallWatch Consortium brings together a wealth of European technology and expertise in a tiny triangular patch called Vigi’Fall that can be worn by the user in a non-intrusive, permanent manner. The interaction between the  device worn by the user, the infrared motion sensors mounted throughout the living area and a central control box ensures the accurate detection of a serious fall and the timely intervention of an emergency medical team. The next phase of the project, FallWatch DEMO, aims to optimise functionality and accuracy even further by incorporating heartbeat monitoring. The  FallWatch/FallWatch DEMO projects have received combined funding of almost €2 million from the European Commission. The consortium is led by French start-up Vigilio S.A. and is a good example of how information /  communication technologies (ICT) can make life easier and better for the elderly.

“It is estimated that over 20 million people aged 65+ suffer a fall every year in  Europe. It is the leading cause of trauma-related deaths in this age group. Immediate medical intervention is therefore crucial and can often mean the difference between life and death,” explains Jean-Eric Lundy, founder of Vigilio S.A and a doctor at the emergency department of the Cochin Hospital in Paris. “Far too often we see elderly patients arrive at the emergency department after lying on the floor for hours unable to call for help. The physical and  psychological deterioration that ensues is often irreparable. The ability to  intervene quickly and provide the medical assistance required can ensure that  a fall does not have a permanent impact on the person’s quality of life.”

How the Vigi’Fall solution works

The solution is based on a sensor system. A biosensor is worn by the user while a number of other sensors are wirelessly attached to walls around the  home, much like domestic burglar alarm sensors. If the user suffers a fall, in addition to the fall signal emitted by the biosensor, the wall-mounted sensors detect the absence of movement and wirelessly relay a signal to a central control box, also located within the home. The control box connects  automatically, via telephone, to a nurse or to a call centre if the fall occurs in the user’s own home. In order to distinguish between real falls and false  alarms, the device is equipped with data-fusion software which allows it to analyse the nature of the fall (with or without impact) and the resulting posture of the patient. In a nursing home, a nurse intervenes immediately.

As a second line of verification for people living alone, an operator at the call  centre attempts to contact the user by telephone. If the phone call goes  unanswered, the family or an emergency rescue team is immediately  mobilised.


The key challenges for the FallWatch Consortium were to miniaturise the  system and to make it easily and comfortably wearable. For this reason, the consortium drew together European partners with a broad range of highly specialised skills ranging from personal security, microelectronics and  biomaterials to nanotechnology, medical adhesives and high performance military and aerospace batteries.


Wearable even in the shower and charged by high-powered batteries, the  patch – once in place on the skin -can simply be forgotten about, with the user secure in the knowledge that, should a fall occur, help will be instantly on its way.

Successful clinical trials and commercial roll-out

The miniaturised Vigi’Fall patch has been successfully trialled in laboratory, hospital, nursing home and domestic environments. Lab trials demonstrated a 90%+ successful detection rate for the biosensor alone without use of the data-fusion software. Trials in real-world environments, which incorporated the data-fusion software, showed an even higher success rate with false alerts practically eliminated.


“We have been involved in trials of the Vigi’Fall solution from the outset and  have seen it constantly evolve in terms of performance to a point where false positive and false negative alerts are rare” says Pr. Anne-Sophie Rigaud, head of the gerontology service at Broca Hospital, Paris. “User-comfort has also  been an important consideration and the current miniaturised patch is  non-intrusive, both from a physical and psychological point of view. Our patients tolerate it well.”


Created in collaboration with Pr. Norbert Noury (INL Lyon), the Vigi’Fall  solution came on the market in November 2012. The various components of the solution are manufactured in France, Italy, Germany and UK and then assembled in France. Contracts have already been signed with  establishments in France, Portugal, Kuwait and with the international  healthcare group Europ Assistance, a partner in the FallWatch Consortium.
Other contracts are currently being negotiated with Switzerland, Denmark,  Ireland and Lithuania. The home version of the solution will be available in the last quarter of 2013 while the second generation of the device, which will also be adapted to US RF standards, will enter into clinical trials in the US and  Europe in September 2013. A commercial version of this new solution is expected to be ready for market at the end of 2014 opening up important new business opportunities. In addition to Europe and the US, several countries in Asia have expressed interest in adopting this unique technology. It is  estimated that 100 qualified jobs will be created in the countries participating in the FallWatch projects in the course of the next 3 years.

Finally, the ability of the second generation device to monitor the wearer’s  heartbeat may also lead to new telemedical applications, in particular for  cardiac patients and epilepsy suffers that do not respond to pharmacological treatment.

“The FallWatch project is a perfect example of the great healthcare advances that can be achieved when the best and brightest of European industry work together”, comments Michael Jennings, European Commission spokesman responsible for research, science, and innovation. “This is the type of  innovation that makes a difference in people’s lives while also contributing to European competitiveness, which the Commission will continue to support under the future EU Research and Innovation Programme Horizon 2020.”

#H2020